Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2016 Jun;9(1):35-41.

Study of the Efficacy, Safety and Tolerability of Low-Molecular-Weight Heparin vs. Unfractionated Heparin as Bridging Therapy in Patients with Embolic Stroke due to Atrial Fibrillation

Farnia Feiz  1 , Reyhane Sedghi  1 , Alireza Salehi  2 , Nahid Hatam  3 , Jamshid Bahmei  3 , Afshin Borhani-Haghighi  4
Affiliations

Study of the Efficacy, Safety and Tolerability of Low-Molecular-Weight Heparin vs. Unfractionated Heparin as Bridging Therapy in Patients with Embolic Stroke due to Atrial Fibrillation

Farnia Feiz et al. J Vasc Interv Neurol. 2016 Jun.

Abstract

Background: Anticoagulation with adjusted dose warfarin is a well-accepted treatment for the prevention of recurrent stroke in patients with atrial fibrillation. Meanwhile, using bridging therapy with heparin or heparinoids before warfarin for initiation of anticoagulation is a matter of debate. We compared safety, efficacy, and tolerability of low-molecular-weight heparin (LMWH) and unfractionated heparin (UFH) as a bridging method in patients with recent ischemic stroke due to atrial fibrillation.

Method: This study was a randomized single-blind controlled trial in patients with acute ischemic stroke due to atrial fibrillation who were eligible for receiving warfarin and were randomly treated with 60 milligrams (mg) of LMWH (enoxaparin) subcutaneously every 12 h, or 1000 units/h of continuous intravenous heparin. The primary efficacy endpoints were recurrence of new ischemic stroke, myocardial infarction and/or death. The primary safety endpoint was central nervous system and/or systemic bleeding.

Results: Seventy-four subjects were recruited. Baseline demographic and clinical characteristics of two groups were matched. Composite endpoint outcome of new ischemic stroke, myocardial infarction, and/or death in follow-up period was seen in 10 subjects (27.03%) in UFH group and in four subjects (10.81%) in LMWH group (p value: 0.136). All hemorrhages and symptomatic central nervous system (CNS) hemorrhages in follow-up period were in 7 (18.9%) and 4 (10.8%) patients in UFH group, in 5 (13.5%), and 3 (8.1%) patients in LMWH group (p values: 0.754 and 0.751), respectively. Drop out and major adverse-effects such as heparin-induced thrombocytopenia and drug hypersensitivity were not seen in any patient.

Conclusion: Enoxaparin can be a safe and efficient alternative for UFH as bridging therapy.

Keywords: Atrial fibrillation; embolic; low-molecular-weight heparin; stroke; unfractionated heparin.

PubMed Disclaimer

Figures

Figure 1.
Figure 1.. Participants’ flow diagram
Figure 2.
Figure 2.
See this image and copyright information in PMC

References

    1. Borhani-Haghighi A, Safari R, Heydari ST, Soleimani F, Sharifian M, Yektaparast-Kashkuli S. Hospital Mortality Associated with Stroke in Southern Iran. Iran J Med Sci. 2013;38:314–20. - PMC - PubMed
    1. Habibzade Fl, Ydollahie M, Roshanpoor M, Haghighi AB. Prevalence of atrial fibrillation in a primary health care nebtre in Fars Province, Islamic Republic of Iran. East Mediterr Health J. 2004;10:147–51. - PubMed
    1. Lip GH, Lane DA. Stroke prevention in atrial fibrillation: a systematic review. JAMA. 2015;313:1950–62. - PubMed
    1. Hart RG, Palacio S, Pearce LA. Atrial fibrillation, stroke, and acute antithrombotic therapy: analysis of randomized clinical trials. Stroke. 2002;33:2722–7. - PubMed
    1. Wessler BS, Kent DM. Controversies in cardioembolic stroke. Curr Treat Options Cardiovasc Med. 2015;17:358. - PMC - PubMed

LinkOut - more resources